阿尔茨海默病试验中疾病进展异质性对治疗效果检测的影响
该模拟研究基于ADNI数据库302例早期AD患者,通过随机分组模拟临床试验并重复10000次,发现18个月时认知结局的效应量95%范围很宽(如CDR-SB从改善0.35到下降0.35)。按APOE ε4或tau分层后异质性更大(CDR-SB范围±0.70分)。近期抗淀粉样蛋白试验结果多落在此范围内,提示需谨慎解读治疗效应。
要点
- 早期AD患者认知轨迹高度异质,18个月CDR-SB效应量95%范围达±0.35分。
- 按APOE ε4或tau分层后组内变异增大,CDR-SB范围可扩至±0.70分。
- 近期抗淀粉样蛋白试验结果多落在上述模拟效应量范围内,解读需谨慎。
核心结论
- 早期AD患者疾病进展存在异质性,按进展相关风险因素分层后异质性增大,需据此预设效应量以检测真实变化。
研究设计与样本
- 模拟研究,从ADNI数据库纳入302例异常淀粉样蛋白PET、MCI或痴呆、MMSE≥24、CDR 0.5且有随访认知评估的个体(年龄73±6.7岁,44%女性,教育16.1±2.7年,69% APOE ε4携带者),随机分组模拟试验并重复10000次。
主要发现
- 所有认知结局的个体轨迹高度变异,18个月时可能效应量的95%范围很宽,例如CDR-SB从改善0.35分到下降0.35分。
- 近期抗淀粉样蛋白试验的结果大多落在这些95%效应量范围内。
- APOE ε4携带者和基线tau异常者组水平下降更快,但组内变异也更大,表现为更宽的95%效应量范围,例如CDR-SB为±0.70分。
临床怎么用
- 在AD试验设计时,应参考本研究所提供的认知结局先验效应量范围,以帮助区分真实治疗效应与疾病进展异质性带来的波动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the influence of heterogeneity in disease progression for detecting treatment effects in Alzheimer disease (AD) trials, using a simulation study. METHODS: Individuals with an abnormal amyloid PET scan, diagnosis of mild cognitive impairment or dementia, baseline Mini-Mental State Examination (MMSE) score ≥24, global Clinical Dementia Rating (CDR) score of 0.5, and ≥1 follow-up cognitive assessment were selected from the Alzheimer's Disease Neuroimaging Initiative database (n = 302, age 73 ± 6.7; 44% female; 16.1 ± 2.7 years of education; 69% APOE ε4 carrier). We simulated a clinical trial by randomly assigning individuals to a "placebo" and "treatment" group and subsequently computed group differences on the CDR-sum of boxes (CDR-SB), Alzheimer's Disease Assessment Scale-cognitive subscale-13 and MMSE after 18 months follow-up. We repeated this simulation 10,000 times to determine the 95% range of effect sizes. We further studied the influence of known AD risk factors (age, sex, education, APOE ε4 status, CSF total tau levels) on the variability in effect sizes. RESULTS: Individual trajectories on all cognitive outcomes were highly variable, and the 95% ranges of possible effect sizes at 18 months were broad (e.g., ranging from 0.35 improvement to 0.35 decline on the CDR-SB). Results of recent anti-amyloid trials mostly fell within these 95% ranges of effect sizes. APOE ε4 carriers and individuals with abnormal baseline tau levels showed faster decline at group level, but also greater within-group variability, as illustrated by broader 95% effect size ranges (e.g., ±0.70 points for the CDR-SB). CONCLUSIONS: Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. We provide guidance for a priori effect sizes on cognitive outcomes for detecting true change, which is crucial for future AD trials.
引用
- Jutten RJ, Sikkes SAM, Van der Flier WM, et al. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology. 2021. PMID: 34550903. doi:10.1212/WNL.0000000000012022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。